Surrey Heartlands

Joint Formulary & PAD

Linzagolix - Uterine fibroids

You are here : Home > Formulary Search > Linzagolix - Uterine fibroids

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
NICE
Restrictions / Comments :
Important
Specialist team initiation and at least a 1-month supply before requesting a transfer of prescribing to primary care.

Documentation

Evidence Review
Linzagolix for uterine fibroids - NICE briefing - November 2024.pdf

PAD Profile

ChemicalSubstance :
Linzagolix
Indication :
Uterine fibroids
Group Name :
Keywords :
Brand Names Include :
Yselty
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1

Other Indications

Below are listed other indications that Linzagolix is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Uterine fibroids.

Committee Recommendations (1)

06 Nov 24 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves linzagolix for the treatment of moderate to severe symptoms of uterine fibroids as recommended by NICE TA996

Linzagolix for this indication will be considered as BLUE (following specialist initiation) on the traffic light system. Specialist will be expected to prescribe a minimum of 1 month of linzagolix before requesting transfer of care to the primary care prescriber.